IP Library Granted Patent US 9,316,633
Granted Patent B2
US 9,316,633 · App. 12/514,992 · Granted Apr 19, 2016

Methods for identifying inhibitors of solute transporters

Inventors: Alan S. Verkman (San Francisco, CA); Marc Harris Levin (San Francisco, CA)
Assignee: The Regents of the University of California
G01N33/5026G01N33/62G01N33/6872G01N33/80G01N2500/10
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,316,633
App. No.
12/514,992
Granted
Apr 19, 2016
Kind
B2
Abstract

Provided herein are methods for identifying and characterizing agents that alter the volume of a cell. Methods are provided for rapid screening and identification of an agent that alters the capability of a small, neutrally charged solute transporter to transport the solute across a cell membrane. The methods described herein may be used to identify and characterize inhibitors of urea transporters, to identify and characterize inhibitors of aquaporins, and to identify and characterize inhibitors of other small, neutrally charged solutes such as glucose.

Claims (3)

1. A method for treating a disease or disorder associated with a urea clearance insufficiency in a subject, said method comprising administering to the subject a composition comprising a pharmaceutically suitable excipient and a compound that inhibits transport of urea by the urea transporter across a cell membrane, wherein the compound is selected from N-benzyl-4-(4-chlorophenylsulfonyl)-2-(2-fluorophenyl)oxazol-5-amine; 5-(methylthio)-4-(phenylsulfonyl)-2-p-tolyl-1H-imidazole; 2-phenyl-4-tosyl-1H-imidazole-5-thiol; and S-2-phenyl-4-(phenylsulfonyl)-1H-imidazol-5-yl benzothioate.

2. The method of claim 1 , wherein the disease or disorder is selected from a cardiovascular disease, syndrome of inappropriate antidiuretic hormone secretion (SIADH), cirrhosis, azotemia, acute renal failure, chronic renal insufficiency, fluid retention, diabetes, and abnormal uresis.

3. The method of claim 1 wherein the urea transporter is Urea Transporter-B (UT-B).

Assignments (2)
CONFIRMATORY LICENSE Recorded Jan 30, 2018
From: UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 045186/0057 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 18, 2010
From: VERKMAN, ALAN S.; LEVIN, MARC HARRIS
To: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Reel/Frame 024099/0235 →
Continuity (4)
Provisional Application 60859665 · Nov 16, 2006
Provisional Application 60859666 · Nov 16, 2006
Provisional Application 60859800 · Nov 16, 2006
Related Publication 20100190796A1 · Jul 29, 2010